OR WAIT 15 SECS
ICON and Tigermed Consulting announced that they have signed an alliance agreement. Through this agreement, ICON and Tigermed will collaborate to offer pharmaceutical and biotechnology clients better access to Chinese patients, utilizing the global reach and experience of the ICON organization, complemented by Tigermed’s in depth knowledge of the Chinese drug development landscape and geographic coverage in China. With headquarters in Shanghai, Tigermed currently operates from 21 offices in China and has over 300 clinical development staff located there.
“Tigermed has a substantial clinical operations presence on the Chinese mainland and this experience, gives them the ability to provide wide-ranging support for clinical drug development in China.” commented Dr. John Hubbard, Group President, Global Clinical Research Services at ICON.
“We are extremely pleased to have signed this agreement with ICON” commented Xiaoping Ye, Chairman and CEO of Tigermed. “This alliance enhances our regional and global capabilities and will enable both ICON and Tigermed to expand the range of clinical research services we can offer to clients in China and around the globe.”